Informed Prostate Cancer Patient Support

EMBARK results Enzalutamide Shows Significant Benefits for High-Risk Biochemically Recurrent Prostate Cancer Patients According to EAU Definition New Analysis from EMBARK Trial Confirms Treatment's Value for European Criteria A recent post hoc analysis of the pivotal EMBARK trial has demonstrated that enzalutamide (Xtandi) provides significant benefits for patients with high-risk biochemically recurrent prostate cancer as defined by the European Association of Urology (EAU) criteria. The results, published in March 2025 in Prostate Cancer and Prostatic Diseases, reinforce the value of this treatment option for a broader patient population than originally studied. Key Findings The analysis showed that in patients meeting the EAU definition of high-risk biochemical recurrence: Metastasis-free survival (MFS) improved significantly with enzalutamide plus leuprolide combination therapy (hazard ratio 0.37) and with enzalutamide monotherapy (hazard ratio 0.57) compared to leuprolide...

New Research Shows Transperineal Biopsies Detect More Prostate Cancer TRANSLATE Trial Adds to Growing Evidence in Biopsy Approach Debate Recent research has shed new light on the ongoing debate between transperineal (TP) and transrectal (TR) prostate biopsy approaches. The TRANSLATE trial, presented at the European Association of Urology Annual Congress in Madrid last month, represents the largest randomized study of its kind with 1,126 participants. Led by Dr. Richard Bryant from the University of Oxford, the research found that the local anesthesia transperineal (LATP) approach detected 5.7% more clinically significant prostate cancers (Grade Group 2 or higher) compared to the transrectal ultrasound (TRUS) approach. Dr. Bryant emphasized that cancer detection is the primary goal of prostate biopsies, making this finding particularly significant. "I've always said that a man doesn't have a biopsy to avoid an infection," Dr. Bryant noted in an interview. "A m...

Representatives from UC San Diego and Pfizer gathered to celebrate the donation recently. PFIZER'S $1 MILLION DONATION TO BOOST PROSTATE CANCER EARLY DETECTION AT UC SAN DIEGO'S MOORES CANCER CENTER Major funding aims to improve screening access for prostate cancer patients in underserved San Diego communities Representatives from UC San Diego and Pfizer gathered to celebrate the donation recently. From left, Matthew Jenusaitis, MD, Chief Administrative Officer for UC San Diego Health; John M. Carethers, MD, Vice Chancellor for Health Sciences; Jeffrey Settleman, Senior Vice President, Chief Scientific Officer, Oncology Research and Development, Pfizer; Diane M. Simeone, MD, Director of Moores Cancer Center; Elena Martinez, Associate Director of Population Science at Moores Cancer Center; Jesse Nodora, Associate Director of Community Outreach and Engagement at Moores Cancer Center; and Kelly Farrell, Head of Business Operations, Oncology Research and La Jolla Affair...

Biodegradable Spacers: A Game-Changer in Reducing Radiation Side Effects for Prostate Cancer Patients For men undergoing radiation therapy for prostate cancer, one of the most significant concerns has been potential damage to the rectum, which sits directly adjacent to the prostate. Recent advances in biodegradable spacer technology are showing remarkable promise in protecting patients from these unwanted side effects, with compelling evidence now available from multiple clinical trials. New Meta-Analysis Confirms Benefits A comprehensive 2025 systematic review and meta-analysis published in Prostate Cancer and Prostatic Diseases has provided definitive evidence supporting the use of biodegradable peri-rectal spacers. The study, led by researchers including Chris Ho-Ming Wong and colleagues, analyzed data from 17 studies involving over 3,200 patients. The results were striking: patients with spacers experienced significantly lower rates of late rectal toxicity (1.62% vs. 9.35%) an...

8 Proven Ways To Stop Nighttime Peeing (Nocturia) In Men 2 - YouTube Dr. Sam Robbins https://www.youtube.com/@drsamrobbins I'll summarize the major points from the text about reducing nighttime urination (nocturia) in men. 8 Ways to Reduce Nighttime Urination (Nocturia) Control liquid intake before bed - Limit or eliminate liquids 2-3 hours before bedtime Avoid diuretics near bedtime - Stay away from coffee, tea, and alcohol which increase urination Be aware of supplement diuretics - Potassium, dandelion root extract, parsley, and horsetail can act as natural diuretics Address prostate health - Get PSA tests and prostate exams as enlargement can cause increased urination Prostate growth is linked to lower testosterone and higher estrogen/DHT levels Consider natural remedies like flax seed before prescription medications Anti-diuretic hormone decline - As we age, we produce less of this hormone that helps retain water Lowering cortisol can help improve anti-diuret...

FDA Expands Pluvicto Approval: New Hope for mCRPC Patients Before Chemotherapy March 28, 2025 In a significant advancement for prostate cancer treatment, the U.S. Food and Drug Administration (FDA) has expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC) who have received prior androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy. What This Means for Patients This expanded approval represents a major shift in treatment options, allowing eligible patients to access this targeted radioligand therapy earlier in their treatment journey, potentially delaying the need for chemotherapy with its associated side effects. The approval is based on results from the Phase III PSMAfore trial, which showed that Pluvicto significantly improved radiographic progression-free survival (...

NeuroSAFE technique v. Standard RARP: A side-by-side comparison of standard RARP versus the NeuroSAFE technique, showing how NeuroSAFE preserves the critical nerve bundles that are often sacrificed in standard procedures The key clinical trial results from the Lancet Oncology study, visualizing: Improved erectile function scores (IIEF-5) at 12 months Higher percentage of patients with no/mild erectile dysfunction Better urinary continence at 3 months (lower ICIQ scores) The color coding helps distinguish between the standard approach (red) and the NeuroSAFE technique (blue),. Breakthrough in Prostate Cancer Surgery Offers Better Quality of Life NeuroSAFE Technique Shows Significant Improvements in Erectile Function and Urinary Continence A clinical trial has confirmed that a specialized surgical technique for prostate cancer patients can dramatically improve quality of life without compromising cancer control. The NeuroSAFE PROOF study, recently published in The Lancet Oncology, ...